Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial

Author(s): Phuoc T. Tran, MD, PhD^1,2,3,4; Kathryn Lowe, BS¹; Hua-Ling Tsai, PhD²; Daniel Y. Song, MD^1,2,3; Arthur Y. Hung, MD⁵; Jason W.D. Hearn, MD⁶; Steven Miller, MD⁷; James A. Proudfoot, PhD⁸; Matthew P. Deek, MD¹; Ryan Phillips, MD, PhD¹; Tamara Lotan, MD⁹; Channing J. Paller, MD^2,3; Catherine H. Marshall, MD²; Mark Markowski, MD, PhD²; Shirl Dipasquale, BSN¹; Samuel Denmeade, MD^2,3; Michael Carducci, MD^2,3; Mario Eisenberger, MD^2,3; Theodore L. DeWeese, MD^1,2,3; Matthew Orton, MD¹⁰; Curtiland Deville, MD¹; Elai Davicioni, PhD⁸; Stanley L. Liauw, MD¹¹; Elisabeth I. Heath, MD⁷; Stephen Greco, MD¹; Neil B. Desai, MD¹²; Daniel E. Spratt, MD¹³; Felix Feng, MD¹⁴; Hao Wang, PhD, MS²; Tomasz M. Beer, MD¹⁵; and Emmanuel S. Antonarakis, MD^2,16

Source: DOI: 10.1200/JCO.22.01662 Journal of Clinical Oncology

Dr. AJ Patel and Dr. Kunal Saigal’s Thoughts

Although not a practice-changing study, this study makes a few points that may be seen in future studies. In biochem-recurrent prostate cancer after RP, novel anti-androgen agents may replace ADT in combination with salvage XRT as they appear to be active and less toxic than traditional ADT. Low/Intermediate risk patients are likely to benefit with median PSA at an accrual of 0.3 in this study, not unlike other similar studies. The role of combination anti-hormone therapy + salvage radiation seems to be solidifying.

PURPOSE

We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men with recurrent prostate cancer after radical prostatectomy (RP).

PATIENTS AND METHODS

Men with biochemically recurrent prostate cancer after RP were enrolled into a randomized, double‐blind, phase II, placebo-controlled, multicenter study of SRT plus ENZA or placebo (ClinicalTrials.gov identifier: NCT02203695). Random assignment (1:1) was stratified by center, surgical margin status (R0 v R1), PSA before salvage treatment (PSA ≥ 0.5 v < 0.5 ng/mL), and pathologic Gleason sum (7 v 8‐10). Patients were assigned to receive either ENZA 160 mg once daily or matching placebo for 6 months. After 2 months of study drug therapy, external-beam radiation (66.6‐70.2 Gy) was administered to the prostate bed (no pelvic nodes). The primary end point was FFPP in the intention-to-treat population. Secondary end points were time to local recurrence within the radiation field, metastasis‐free survival, and safety as determined by frequency and severity of adverse events.

RESULTS

Eighty-six (86) patients were randomly assigned, with a median follow-up of 34 (range, 0-52) months. Trial arms were well balanced. The median pre-SRT PSA was 0.3 (range, 0.06-4.6) ng/mL, 56 of 86 patients (65%) had extraprostatic disease (pT3), 39 of 86 (45%) had a Gleason sum of 8-10, and 43 of 86 (50%) had positive surgical margins (R1). FFPP was significantly improved with ENZA versus placebo (hazard ratio [HR], 0.42; 95% CI, 0.19 to 0.92; P = .031), and 2-year FFPP was 84% versus 66%, respectively. Subgroup analyses demonstrated differential benefit of ENZA in men with pT3 (HR, 0.22; 95% CI, 0.07 to 0.69) versus pT2 disease (HR, 1.54; 95% CI, 0.43 to 5.47; P_interaction = .019) and R1 (HR, 0.14; 95% CI, 0.03 to 0.64) versus R0 disease (HR, 1.00; 95% CI, 0.36 to 2.76; P_interaction = .023). There were insufficient secondary end point events for analysis. The most common adverse events were grade 1-2 fatigue (65% ENZA v 53% placebo) and urinary frequency (40% ENZA v 49% placebo).

CONCLUSION

SRT plus ENZA monotherapy for 6 months in men with PSA-recurrent high-risk prostate cancer after RP is safe and delays PSA progression relative to SRT alone. The impact of ENZA on distant metastasis or survival is unknown at this time.

Author Affiliations

¹Department of Radiation Oncology & Molecular Radiation Sciences, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD ²Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD ³The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD ⁴Current address: Department of Radiation Oncology, University of Maryland, Baltimore, MD ⁵Department of Radiation Medicine, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR ⁶Department of Radiation Oncology, University of Michigan, Ann Arbor, MI ⁷Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI ⁸Veracyte, San Diego, CA ⁹Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD ¹⁰Department of Radiation Oncology, Indiana University Health Arnett, Lafayette, IN ¹¹Department of Radiation Oncology and Cellular Oncology, University of Chicago, Chicago, IL ¹²Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX ¹³Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH ¹⁴Departments of Medicine, Radiation Oncology and Urology, University of California San Francisco, San Francisco, CA ¹⁵OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR ¹⁶Department of Medicine, University of Minnesota, Minneapolis, MN

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

An important post-hoc analysis from ARCHES and PROSPER that quantifies something we've suspected clinically, roughly 1 in 4 enzalutamide-treated patients who progress radiographically have no prostate-specific antigen (PSA) rise, and the majority won't meet PCWG2/3 PSA progression criteria. Liver metastases were 5-fold more common at radiographic progression on enzalutamide versus control, suggesting lineage plasticity and AR-independent clones are the culprit. Bottom line for practice: don't wait for PSA to rise before imaging your metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) patients on ARPIs, periodic cross-sectional imaging, especially in the first two years, is warranted regardless of PSA trend.

Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer

Solid pragmatic phase II showing oxybutynin 2.5mg and 5mg BID (twice a day) both beat placebo for hot flash reduction in men on androgen-deprivation therapy (ADT), with no serious toxicities beyond expected dry mouth. Given that venlafaxine failed in this population and megestrol/medroxyprogesterone carry real concerns, this gives us an evidence-based option we can feel good about reaching for, especially in patients who also have urinary symptoms. Neurokinin B (NKB) antagonists are coming but not yet studied here, so oxybutynin fills a real gap now.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Moving PARP inhibition earlier into the hormone-sensitive androgen pathway modulation–sensitive (APMS) setting, this trial shows talazoparib plus enzalutamide cuts the risk of progression or death in half (HR 0.48) in HRR-altered metastatic prostate cancer, with an impressive 3-year progression-free survival (PFS) of 77% versus 56%. The benefit extends beyond BRCA1/2 to ATM and CDK12 as well, which is clinically meaningful given that two-thirds of this population was non-BRCA.

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Overall survival was 78.9% in the combination group compared with 69.5% in the leuprolide-alone group (HR 0.60). Enzalutamide monotherapy resulted in an overall survival of 73.1%, which was not statistically significant. We were already aware of the progression-free survival benefit; now we have overall survival data. This case was also presented in the MOC questions, where the correct answer was to add enzalutamide for a patient with a rising PSA on an LHRH agonist without imaging evidence of disease.

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Metformin did not significantly reduce the risk of disease progression compared with active surveillance in patients with low-risk prostate cancer.